Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
112.3 AUD | +2.79% | +4.71% | +17.14% |
04-02 | Pro Medicus Limited authorizes a Buyback Plan. | CI |
04-01 | Pro Medicus Limited announces an Equity Buyback for 10,442,488 shares, representing 10% of its issued share capital. | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With an expected P/E ratio at 146.96 and 112.01 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.14% | 7.56B | C- | ||
+3.31% | 32.09B | C | ||
+21.60% | 3.85B | B- | ||
-17.44% | 3.18B | C- | ||
-27.80% | 1.23B | B | ||
-31.01% | 1.17B | - | ||
-34.81% | 911M | - | ||
+3.51% | 906M | C | ||
-25.45% | 860M | - | C+ | |
-13.92% | 730M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PME Stock
- Ratings Pro Medicus Limited